Cancer Research and Investment Opportunities

FOR INVESTORS
Access company scores and reports, investor briefs, webinars and more through our Investor Portal
Become a Member
Featured
Dr Ronald A. DePinho
Dr Ronald A. DePinho

Dr. Ronald A. DePinho is a distinguished university professor and past president at MD Anderson Cancer Center. Ron is a global health leader, entrepreneur, physician and leading scientist in the fields of cancer and aging. In addition to his research, he has launched 3 biotech companies (Tvardi, Asylia, and Nirogy) focused on cancer, inflammation and fibrosis, with potential applications to COVID-19.

He specializes in strategic planning and financial analysis, clean energy technologies, energy and water issues, and international and governmental policies. From 2006 to 2010, he was director of the Strategic Energy Analysis Center at NREL. In addition to his NREL responsibilities, he is an author and expert reviewer for the Intergovernmental Panel on Climate Change (IPCC) Special Report on Renewable Energy and a member of the U.S. government review panel for the IPCC reports on climate change.

Prior to joining NREL, he was a management consultant to clean energy companies, providing strategy, development, and market counsel. Previous positions include: director of strategic marketing and business development at Network Photonics; director of media gateway products and strategic planning manager at Lucent Technologies (now Avaya); and vice president of business development for Amonix Inc.

 

INTRODUCTION

Cancer exacts a steep social and economic toll, especially as an aging world population creates increased cancer rates. The investment community plays a critical role in supporting the conversion of entrepreneurial innovation into products and platforms that reduce the burden of cancer throughout the world. A viable investment strategy rests on an understanding of the scientific and technological advances that are rapidly being made in the cancer field, and where those advances are heading. These breakthroughs are impacting all aspects of cancer treatment, from drug development to integrated pathways of care delivery.


HealthChristian HodgsonExpert Analysis